Capsular sialic acid prevents activation of the alternative complement pathway by type III, group B streptococci.
D000818:Animals; D000942:Antigens, Bacterial / Q000276:immunology; D003167:Complement Activation; D003175:Complement C2 / Q000172:deficiency; D003176:Complement C3 / Q000378:metabolism; D003179:Complement C3b / Q000378:metabolism; D003170:Complement Pathway, Alternative; D006801:Humans; D007231:Infant, Newborn; D009439:Neuraminidase / Q000494:pharmacology; D011135:Polysaccharides, Bacterial / Q000276:immunology; D011817:Rabbits; D012756:Sheep; D012794:Sialic Acids / Q000494:pharmacology*; D013292:Streptococcus agalactiae / Q000254:growth & development / Q000276:immunology*
D000942:Antigens, Bacterial; D003175:Complement C2; D003176:Complement C3; D011135:Polysaccharides, Bacterial; D012794:Sialic Acids; D003179:Complement C3b; D009439:Neuraminidase